Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cyprus Business Journal.
Press releases published on August 7, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) …

ThreeSixty Journalism Concludes 2025 Storytelling Institute for Local Students
ST. PAUL, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ThreeSixty Journalism has successfully concluded its 2025 Multimedia Storytelling Institute, a three-week summer camp held July 7 through July 24 at the University of St. Thomas College of Arts and …

LegalZoom Reports Strong Second Quarter 2025 Financial Results, Raises 2025 Revenue Growth Expectations
Solid execution with second quarter revenue exceeding high end of outlook range Second quarter revenue of $192.5 million, up 9% year-over-year Subscription revenue of $119.9 million, an increase of 10% year-over-year, reflecting outstretched progress in …

EXP’s Expansion marks first milestone by joining SR 400 Peach Partners in financial close of Georgia SR 400 Express Lanes Project
ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- EXP, a global engineering, architecture, design and consulting firm, recently established a new infrastructure sector led by business development leader and Senior Vice President Kyle Henry. The new sector, …

Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext …

Galapagos creëert nieuw inschrijvingsrechtenplan
Mechelen, België; 7 augustus 2025, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext …

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated …

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
Q2 revenue of $29.2 million, increased 55% year-over-year Q2 gross profit increased 59% year-over-year to $18.6 million Paid down $4.5 million of principal on outstanding term loan during Q2 Increased full year 2025 guidance to a revenue range between $104 …

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025 Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee completed fourth …

Senvest Capital Inc. Reports Results for the Second Quarter Ended June 30, 2025
MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported net income attributable to common shareholders of $226.3 million or $92.75 per share for the three months ended June 30, 2025. This compares to a net loss attributable to …

Belpointe OZ’s Aster & Links Wins Two Awards
SARASOTA, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belpointe PREP, LLC (“Belpointe OZ,” “we,” “us,” “our” or the “Company”), the first and only publicly traded Qualified Opportunity Fund (NYSE American: OZ), is proud to announce that its flagship development, …

Stereotaxis Reports 2025 Second Quarter Financial Results
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are …

Senvest Capital Inc. annonce ses rėsultats pour le trimestre terminé le 30 juin 2025
MONTRĖAL, 07 août 2025 (GLOBE NEWSWIRE) -- Senvest Capital Inc. a annoncé aujourd’hui un résultat net attribuable aux actionnaires ordinaires de 226,3 M$ ou 92,75 $ par action pour les trois mois terminés le 30 juin 2025. Pour la période correspondante de …

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug …

CompoSecure Reports Record Second Quarter 2025 Financial Results
Operating results exceed expectations across all key metrics Strong top line growth driven by domestic programs from traditional banks and fintechs Record profitability demonstrates early results from CompoSecure Operating System Raising previously issued …

Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, …

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension …

Apyx Medical Corporation Reports Second Quarter 2025 Financial Results
Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025 Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial procedures Based …

Turtle Beach Corporation Announces Second Quarter 2025 Financial Results and Reiterates Full Year Guidance
–Delivered Net Revenue of $56.8 Million– –Gross Margin Improved to 32.2%, an Increase of 200 Basis Points Compared to Prior Year– –Net Loss of $2.9 Million Compared to Net Loss of $7.5 Million in Prior Year– –Adjusted EBITDA of ($3.0) Million– –Refinanced …

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial of claseprubart …